Why Galectin Therapeutics Stock Bolted Higher Today

Shares of the clinical-stage biotech Galectin Therapeutics (NASDAQ: GALT) are ripping higher today after the company announced a new patent covering the use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent reportedly extends the experimental drug's period of exclusivity until 2032.As of 12:25 p.m. EDT, Galectin's shares still are up by a respectable 13.3% on the back of this news. Image source: Getty Images.Continue reading

Topics:  galectin therapeutics nasdaq   galt    gr-md-02   edt   galectin   images   higher today   shares   patent   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News